260 related articles for article (PubMed ID: 30472757)
1. Engineering synucleinopathy-resistant human dopaminergic neurons by CRISPR-mediated deletion of the SNCA gene.
Chen Y; Dolt KS; Kriek M; Baker T; Downey P; Drummond NJ; Canham MA; Natalwala A; Rosser S; Kunath T
Eur J Neurosci; 2019 Feb; 49(4):510-524. PubMed ID: 30472757
[TBL] [Abstract][Full Text] [Related]
2. Recombinant pro-CTSD (cathepsin D) enhances SNCA/α-Synuclein degradation in α-Synucleinopathy models.
Prieto Huarcaya S; Drobny A; Marques ARA; Di Spiezio A; Dobert JP; Balta D; Werner C; Rizo T; Gallwitz L; Bub S; Stojkovska I; Belur NR; Fogh J; Mazzulli JR; Xiang W; Fulzele A; Dejung M; Sauer M; Winner B; Rose-John S; Arnold P; Saftig P; Zunke F
Autophagy; 2022 May; 18(5):1127-1151. PubMed ID: 35287553
[TBL] [Abstract][Full Text] [Related]
3. CRISPR-Cas9-Edited SNCA Knockout Human Induced Pluripotent Stem Cell-Derived Dopaminergic Neurons and Their Vulnerability to Neurotoxicity.
Inoue S; Nishimura K; Gima S; Nakano M; Takata K
Biol Pharm Bull; 2023; 46(3):517-522. PubMed ID: 36858582
[TBL] [Abstract][Full Text] [Related]
4. Modeling native and seeded Synuclein aggregation and related cellular dysfunctions in dopaminergic neurons derived by a new set of isogenic iPSC lines with SNCA multiplications.
Iannielli A; Luoni M; Giannelli SG; Ferese R; Ordazzo G; Fossati M; Raimondi A; Opazo F; Corti O; Prehn JHM; Gambardella S; Melki R; Broccoli V
Cell Death Dis; 2022 Oct; 13(10):881. PubMed ID: 36261424
[TBL] [Abstract][Full Text] [Related]
5. Induced Pluripotent Stem Cell-Derived Dopaminergic Neurons from Familial Parkinson's Disease Patients Display α-Synuclein Pathology and Abnormal Mitochondrial Morphology.
Diao X; Wang F; Becerra-Calixto A; Soto C; Mukherjee A
Cells; 2021 Sep; 10(9):. PubMed ID: 34572052
[TBL] [Abstract][Full Text] [Related]
6. Host-to-graft propagation of inoculated α-synuclein into transplanted human induced pluripotent stem cell-derived midbrain dopaminergic neurons.
Gima S; Oe K; Nishimura K; Ohgita T; Ito H; Kimura H; Saito H; Takata K
Regen Ther; 2024 Mar; 25():229-237. PubMed ID: 38283940
[TBL] [Abstract][Full Text] [Related]
7. Alpha-synuclein dynamics in induced pluripotent stem cell-derived dopaminergic neurons from a Parkinson's disease patient (PARK4) with SNCA triplication.
Fukusumi H; Togo K; Sumida M; Nakamori M; Obika S; Baba K; Shofuda T; Ito D; Okano H; Mochizuki H; Kanemura Y
FEBS Open Bio; 2021 Feb; 11(2):354-366. PubMed ID: 33301617
[TBL] [Abstract][Full Text] [Related]
8. Grafts Derived from an α-Synuclein Triplication Patient Mediate Functional Recovery but Develop Disease-Associated Pathology in the 6-OHDA Model of Parkinson's Disease.
Shrigley S; Nilsson F; Mattsson B; Fiorenzano A; Mudannayake J; Bruzelius A; Ottosson DR; Björklund A; Hoban DB; Parmar M
J Parkinsons Dis; 2021; 11(2):515-528. PubMed ID: 33361611
[TBL] [Abstract][Full Text] [Related]
9. Midbrain organoids with an
Mohamed NV; Sirois J; Ramamurthy J; Mathur M; Lépine P; Deneault E; Maussion G; Nicouleau M; Chen CX; Abdian N; Soubannier V; Cai E; Nami H; Thomas RA; Wen D; Tabatabaei M; Beitel LK; Singh Dolt K; Karamchandani J; Stratton JA; Kunath T; Fon EA; Durcan TM
Brain Commun; 2021; 3(4):fcab223. PubMed ID: 34632384
[No Abstract] [Full Text] [Related]
10. Downregulation of SNCA Expression by Targeted Editing of DNA Methylation: A Potential Strategy for Precision Therapy in PD.
Kantor B; Tagliafierro L; Gu J; Zamora ME; Ilich E; Grenier C; Huang ZY; Murphy S; Chiba-Falek O
Mol Ther; 2018 Nov; 26(11):2638-2649. PubMed ID: 30266652
[TBL] [Abstract][Full Text] [Related]
11. LGALS3 (galectin 3) mediates an unconventional secretion of SNCA/α-synuclein in response to lysosomal membrane damage by the autophagic-lysosomal pathway in human midbrain dopamine neurons.
Burbidge K; Rademacher DJ; Mattick J; Zack S; Grillini A; Bousset L; Kwon O; Kubicki K; Simon A; Melki R; Campbell EM
Autophagy; 2022 May; 18(5):1020-1048. PubMed ID: 34612142
[TBL] [Abstract][Full Text] [Related]
12. Impact of α-synuclein pathology on transplanted hESC-derived dopaminergic neurons in a humanized α-synuclein rat model of PD.
Hoban DB; Shrigley S; Mattsson B; Breger LS; Jarl U; Cardoso T; Nelander Wahlestedt J; Luk KC; Björklund A; Parmar M
Proc Natl Acad Sci U S A; 2020 Jun; 117(26):15209-15220. PubMed ID: 32541058
[TBL] [Abstract][Full Text] [Related]
13. REST Protects Dopaminergic Neurons from Mitochondrial and α-Synuclein Oligomer Pathology in an Alpha Synuclein Overexpressing BAC-Transgenic Mouse Model.
Ryan BJ; Bengoa-Vergniory N; Williamson M; Kirkiz E; Roberts R; Corda G; Sloan M; Saqlain S; Cherubini M; Poppinga J; Bogtofte H; Cioroch M; Hester S; Wade-Martins R
J Neurosci; 2021 Apr; 41(16):3731-3746. PubMed ID: 33563726
[TBL] [Abstract][Full Text] [Related]
14. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.
Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D
J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146
[TBL] [Abstract][Full Text] [Related]
15. Cellular α-synuclein pathology is associated with bioenergetic dysfunction in Parkinson's iPSC-derived dopamine neurons.
Zambon F; Cherubini M; Fernandes HJR; Lang C; Ryan BJ; Volpato V; Bengoa-Vergniory N; Vingill S; Attar M; Booth HDE; Haenseler W; Vowles J; Bowden R; Webber C; Cowley SA; Wade-Martins R
Hum Mol Genet; 2019 Jun; 28(12):2001-2013. PubMed ID: 30753527
[TBL] [Abstract][Full Text] [Related]
16. Up-regulation of SNCA gene expression: implications to synucleinopathies.
Tagliafierro L; Chiba-Falek O
Neurogenetics; 2016 Jul; 17(3):145-57. PubMed ID: 26948950
[TBL] [Abstract][Full Text] [Related]
17. An Isogenic Collection of Pluripotent Stem Cell Lines With Elevated α-Synuclein Expression Validated for Neural Induction and Cortical Neuron Differentiation.
Natalwala A; Behbehani R; Yapom R; Kunath T
Front Cell Dev Biol; 2022; 10():898560. PubMed ID: 35712660
[TBL] [Abstract][Full Text] [Related]
18. Sequential or Simultaneous Injection of Preformed Fibrils and AAV Overexpression of Alpha-Synuclein Are Equipotent in Producing Relevant Pathology and Behavioral Deficits.
Negrini M; Tomasello G; Davidsson M; Fenyi A; Adant C; Hauser S; Espa E; Gubinelli F; Manfredsson FP; Melki R; Heuer A
J Parkinsons Dis; 2022; 12(4):1133-1153. PubMed ID: 35213388
[TBL] [Abstract][Full Text] [Related]
19. Mutant α-Synuclein Overexpression Induces Stressless Pacemaking in Vagal Motoneurons at Risk in Parkinson's Disease.
Lasser-Katz E; Simchovitz A; Chiu WH; Oertel WH; Sharon R; Soreq H; Roeper J; Goldberg JA
J Neurosci; 2017 Jan; 37(1):47-57. PubMed ID: 28053029
[TBL] [Abstract][Full Text] [Related]
20. CRISPR-Cas9 Gene Editing Protects from the A53T-SNCA Overexpression-Induced Pathology of Parkinson's Disease
Yoon HH; Ye S; Lim S; Jo A; Lee H; Hong F; Lee SE; Oh SJ; Kim NR; Kim K; Kim BJ; Kim H; Lee CJ; Nam MH; Hur JW; Jeon SR
CRISPR J; 2022 Feb; 5(1):95-108. PubMed ID: 35191750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
